Merck Stock Downgraded Despite Cancer Vaccine Success

Merck's stock has been downgraded despite a significant win with its cancer vaccine, as analysts note a stretched valuation and a strong but potentially overvalued pipeline. This comes after a period of positive news for the pharmaceutical company.

20 Aug, 20:20 — 20 Aug, 20:20

Post Share

Sources

Showing 1 of 2 sources

Barron'sHigh13d ago

Why Merck Stock Got Downgraded After a Massive Cancer-Vaccine Win - Barron's

Why Merck Stock Got Downgraded After a Massive Cancer-Vaccine Win Barron's

Read full article →

Coverage Timeline

First report: Barron's · 20 Aug, 20:20|Full coverage: 2 · 18h|Window: 18h

Left-leaningCenterRight-leaning

Barron's20 Aug, 20:20First to report

Why Merck Stock Got Downgraded After a Massive Cancer-Vaccine Win - Barron's

18h later

investing-com21 Aug, 14:47Latest update

Merck Stock Downgraded Despite Cancer Vaccine Success

Sources

Why Merck Stock Got Downgraded After a Massive Cancer-Vaccine Win - Barron's

Coverage Timeline

Why Merck Stock Got Downgraded After a Massive Cancer-Vaccine Win - Barron's

Merck stock analysis: great pipeline at a stretched valuation

Related Stories

Homeland Security Secretary’s Plane Makes Emergency Landing After Engine Failure

Berkshire Hathaway Signals Long-Term Commitment to Japanese Trading Houses

South Korean Utility Proposes $15 Billion Upfront Power Payment From Samsung

Chevron Confirms Expansion of Oil Operations in Venezuela